Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed findings of 2 phase 4 real-world studies on tildrakizumab, which showed that patients achieved significant improvement in severity and quality of life by week 4 of treatment.
Real-world patients with moderate to severe psoriasis showed significant improvement in severity and quality of life by week 4 of treatment with tildrakizumab, said Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America.
Rozzo served as coauthor of 2 studies presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting, titled “Real-world Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Plaque Psoriasis: Week 28 Interim Analysis of a Phase 4 Study” and “A Phase 4, Real-world Study of Tildrakizumab in Moderate-to-Severe Psoriasis: Week 28 Interim Analysis.”
Transcript
Can you discuss findings of the phase 4 real-world studies presented at AAD 2022 investigating the impact of tildrakizumab on severity, quality of life in moderate to severe psoriasis?
One of the most encouraging parts, I think, for patients and for providers, is that the clinical efficacy was significantly improved by week 4 after just 1 injection. But also the quality of life, as assessed through the Psychological [General] Well-Being Index, as well as through Dermatology Life Quality Index, which is more familiar to many dermatologists, also showed significant improvement by week 4.
Patients continued to improve and maintained their improvement through week 28. So, this is not something you'll necessarily see all the time in real-world studies. It's very gratifying to see that and see that the results are very consistent with the phase 3 clinical trials.
How has efficacy of tildrakizumab fared across racial/ethnic subgroups in patients with moderate to severe psoriasis?
During our phase 3 trials, we assessed the efficacy and safety across a variety of ethnic and racial groups. And it was good to see that there was no difference. It worked equally well in patients across demographic groups.
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More